Skip to main content

Table 3 Comparison of patients with germline TET2 mutation alone and not

From: Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation

Patient’s parameters TET2 GM-Alone
(n = 11)
TET2 GM-Others
(n = 22)
P
Age(Y)median(range) 46(16–74) 55.5(27–82) 0.114
Male (%) 7(63.6%) 11(50.0%) 0.712
VAF (%) median(range) 50.23(48.2–54.16) 50.70(47.5–55.0) 0.611
Cytogenetics    0.384
 Normal or -Y alone 6(54.5%) 12(54.5%)  
 Complex 0(0.0%) 2(9.1%)  
 Others 1(9.1%) 5(22.7%)  
 unknown 4(36.4%) 3(13.6%)  
Diagnosis    0.026
 MDS/AML 2(18.2%) 14(63.6%)  
 Others 9(72.8%) 8(22.7%)  
Peripheral blood median(range)   
 Hemoglobin (g/L) 73(52–160) 83(27.0–137) 0.711
 WBC (× 109/L) 4.43(0.23–33.38) 4.72(1.26–13.25) 0.749
 Platelet (×109/L) 124(3–611) 62(8–348) 1
 Absolute Neutrophils (× 109/L) 1.83(0.0–25.37) 1.53(0.19–8.86) 0.711
 Absolute Lymphocyte (×109/L) 1.80(0.2–3.0) 1.19(0.3–2.66) 0.223
 Absolute Monocyte (×109/L) 0.23(0.0–0.83) 0.24(0.0–0.760) 0.863
 Total Eosinophils (×109/L) 0.2(0–1.0) 0.01(0–0.49) 0.065
Bone marrow (%) median (range)
 Myeloblast 1(0.5–4.0) 4(1.0–48) 0.004
 Mature Lymphocyte 21(5.0–70.0) 13.25(5.5–49) 0.145
 Mature Monocyte 1.5(0.5–2.0) 1.5(0.5–21.0) 0.438
 Basophilic Erythroblast 1.5(0.5–2.0) 1.5(0.5–5.0) 0.71
 Polychromatophilic erythroblast 9.0(3.0–17.5) 8.5(1.5–25.5) 0.76
 Acidophilic Erythroblast 16.5(4–39) 15.5(2.5–51.5) 0.89
  1. Aberration: Age (Y), Age (year); n, number of patients; TET2 GM-Alone, TET2 germline mutation alone; TET2 GM-others, TET2 germline mutation simultaneously with other gene mutations; VAF, variate allele frequency; MDS/AML, myelodysplastic syndrome/acute myeloid leukemia
  2. A value of P less than 0.05 was considered statistically significant